Beta Bionics, Inc. (NASDAQ:BBNX) Shares Shorted: Short Interest Down 43.1% in September

Beta Bionics, Inc. (NASDAQ:BBNX) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totaling 6,046,389 shares, a drop of 43.1% from the September 15th total of 10,617,768 shares. Based on an average trading volume of 1,859,712 shares, the days-to-cover ratio is presently 3.3 days. Currently, 14.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

BBNX has been the subject of a number of research analyst reports. Barclays started coverage on shares of Beta Bionics in a report on Tuesday, October 6th. They set an “overweight” rating and a $30.00 price objective for the company. Jefferies Financial Group started coverage on Beta Bionics in a research note on Monday, October 12th. They issued a “buy” rating and a $30.00 target price on the stock. Bank of America raised their price target on Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Tuesday, September 15th. Leerink Partners raised their price target on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Finally, Robert W. Baird lifted their price target on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Beta Bionics Price Performance

NASDAQ BBNX traded down $0.96 on Friday, reaching $16.35. 660,832 shares of the company’s stock traded hands, compared to its average volume of 1,051,882. Beta Bionics has a 12 month low of $8.80 and a 12 month high of $32.71. The stock has a 50-day simple moving average of $19.04 and a 200 day simple moving average of $15.19. The stock has a market cap of $735.59 million, a PE ratio of -9.91 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $32.01 million for the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. As a group, analysts anticipate that Beta Bionics will post -2.02 EPS for the current year.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The securities lawsuit covers investors who purchased Beta Bionics shares between July 30, 2025, and February 24, 2026. The claims reportedly relate to alleged disclosures concerning the FDA’s concerns about the company’s iLet automated insulin-delivery system and the impact of those revelations on the stock. The allegations have not been proven. Hagens Berman securities class-action announcement
• Negative Sentiment: Additional notices cite allegations that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints. If substantiated, such claims could increase regulatory, litigation, and reputational risks for the company. SueWallSt Beta Bionics lawsuit notice
• Negative Sentiment: The high volume of investor-law-firm announcements keeps attention focused on legal exposure and prior share-price losses, weighing on investor confidence. The lead-plaintiff deadline is November 3, 2026. Kaplan Fox lead-plaintiff deadline notice
• Neutral Sentiment: Insider Mark Hopman sold 775 shares for approximately $13,446, reducing his direct ownership by 1.38%. Because the sale was small relative to his remaining 55,334 shares, it is a modest signal but may add some pressure to sentiment. SEC insider transaction filing

Insider Buying and Selling

In other news, CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares in the company, valued at $3,045,713.58. The trade was a 4.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of the business’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the transaction, the director owned 19,564 shares of the company’s stock, valued at $449,972. This trade represents a 24.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,472 shares of company stock valued at $1,920,481 in the last three months. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Beta Bionics

A number of large investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in shares of Beta Bionics during the second quarter valued at about $2,524,000. Bank of America Corp DE purchased a new position in shares of Beta Bionics in the second quarter worth about $8,566,000. Man Group plc purchased a new position in shares of Beta Bionics in the second quarter worth about $419,000. Legal & General Group Plc bought a new stake in shares of Beta Bionics in the 2nd quarter valued at about $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics in the 2nd quarter valued at about $172,000.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.